Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 17/04/2026 BST			5-day change	1st Jan Change
1,804.00 ^DKK	+0.78%		+0.78%	-11.00%

04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI

UBS Lowers Price Target for Genmab to 2,600 Danish Kroner (from 2,750), Reiterates Buy

Published on 03/06/2026 at 07:28 am GMT

Finwire - Translated by Marketscreener - See original

GENMAB A/S

+0.78%

UBS has lowered its price target for Genmab to 2,600 Danish kroner (previously 2,750), while reiterating its buy recommendation.

Latest news about Genmab A/S

04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI
04-14	Genmab Posts Higher Darzalex Net Sales in Q1	MT
04-14	Genmab Reports Q1 Net Sales of DARZALEX	MT
04-14	Genmab reports Darzalex sales of $3.96 billion in Q1	FW
04-14	Genmab Q1 Darzalex net sales at $3,964 mln	RE
04-14	Jyske Bank upgrades Genmab to Buy from Hold, sets price target at DKK 2,300 - BN	FW
04-14	Genmab Combo Therapy Shows Safe Profile in Ovarian Cancer Trial	MT
04-13	Genmab Says Rinatabart Sesutecan Combination Tolerable in Patients With Advanced Ovarian Cancer	MT
04-13	Genmab reports promising safety data in clinical trial	FW
04-13	Genmab says phase 1/2 Rainfol-01 data show Rina-S and bevacizumab combination tolerable	RE
04-13	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
04-10	Nordic Equities in North America - Ericsson slips 0.5 percent	FW
04-09	Nordic Equities in North America - Autoliv slips 0.7 percent	FW
04-07	Nordic Stocks in North America - Astra Zeneca rose 2.1 percent	FW

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

2,973

Sector

Biotechnology & Medical Research

Calendar

05-07 - Earnings release - Q1 2026

More about the company